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Thymidylate Synthase (TS) is the key enzyme for DNA synthesis pathways and is inhibited by 5-Fluorouracil (5FU). The aim of
this work was to study TS expression and the proliferation rate in the diﬀerent histological types of colorectal carcinoma (CRC). 50
patients with CRC were included in this study and evaluated immunohistochemically using the monoclonal antibodies, TS106 and
Ki67. 20 tumours were of the intestinal type, 15 cases were signet ring cell carcinoma (SRCCs) and 15 cases were ‘‘mixed-type’’, with
at least two diﬀerent histological components. Intestinal and mucinous histotypes were positive for TS and Ki67, while ‘‘signet ring
cell’’ samples were negative or showed only weak and focal positivity for both the TS and Ki67 antibodies. Our results show that
signet ring cells (that are also often present in intestinal and mucinous carcinomas), are in the post-mitotic phase of the cell cycle and
show a low proliferation index and TS expression. As TS is the key enzyme for DNA synthesis pathways and is inhibited by 5-ﬂuor-
ouracil (5FU), we can hypothesise that TS expression levels in the diﬀerent histotypes of CRC could aﬀect the potential responsive-
ness of these tumours to ﬂuoropyrimidine chemotherapy, with a low eﬃcacy being expected in signet ring cell areas.
 2004 Elsevier Ltd. All rights reserved.
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Colorectal carcinoma (CRC) is one of the most fre-
quent neoplasms in Western society. The modulation
of 5-ﬂuorouracil (5FU) with folinic acid is one of the
main therapies for this neoplastic disease, but only 20–
40% of advanced tumours respond to this treatment
[1]. Recently, new strategies have introduced a combina-
tion of 5FU with oxaliplatin and/or irinotecan; however,
‘‘5FU is the most common chemotherapeutic agent used0959-8049/$ - see front matter  2004 Elsevier Ltd. All rights reserved.
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E-mail address: sanguedolce@unipa.it (R. Sanguedolce).in the treatment of colorectal cancer’’ [2] and today is
still present in all drug combinations.
The main target of 5FU is thymidylate synthase (TS),
an enzyme that is necessary for DNA synthesis because
it is involved in the pyrimidine synthesis pathway. Nev-
ertheless, the role of TS expression in the response of pa-
tients to 5FU is still debated.
Until now, the literature contains sparse data relating
the cancer histotype with the outcome of chemotherapy
and the data existing concern only gastric cancer [3]. To
the best of our knowledge, TS expression has been re-
lated to Dukes stage in colorectal cancer [4,5], but not
to the cancer histotype. Moreover, histological type is
not statistically signiﬁcant in most studies of prognostic
Table 1
Clinico-pathological features of patients included in the study
Patients n
Gender M 31
F 19
Age (years) <60 12
60–70 17
70> 21
Tumour site Right colon 23
Left colon 15
Rectum 12
Grading G1 11
G2 27
G3 12
Dukes staging A 5
B 16
C 24
D 5
M, males; F, females.
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high-grade: speciﬁcally, signet ring cell carcinoma
(SRCC) and small cell carcinoma [6]. SRCCs are a rare
form of CRCs. The incidence rate of the primary SRCC
is very low, approximately 2–3% of all CRCs [7], but the
signet ring cell histotype component is frequently pre-
sent in many intestinal carcinomas.
This component grows in a diﬀuse fashion, with little
or no glandular formation and, in contrast with the pat-
tern in mucinous carcinomas, these tumours synthesise
all their mucin in the intracellular space [8]. This intra-
cellular accumulation of mucin results in the displace-
ment of the nucleus and cancer cells acquire the
typical signet ring conﬁguration. In some cases, there
is a mixture of both extracellular and intracellular mucin
formation. Thus, clinical and histological classiﬁcation
of SRCCs remains controversial because they are some-
times considered to be a subtype of ‘‘mucinous carcino-
mas’’ [9]. More often, they are considered to be a
separate histotype, included in the group of CRC rare
histotypes with the worse prognoses and with drug-re-
sistant tumours [6,10].
In the present study, we analysed 50 CRCs by means
of an immunohistochemistry (IHC) assay to assess TS
expression with the aim of identifying a relationship be-
tween TS-positivity and the cancer histotype.
As TS is a cell cycle enzyme and is present in prolif-
erating cells [11,12], we also studied the expression of
Ki67 (Mib1), a monoclonal antibody which recognises
the nuclei of proliferating cells throughout the cell cycle,
except during the G0 and early G1 phases, to try to ﬁnd
any relationship between tumour histotype, TS levels,
and the proliferation index.
The IHC assay was chosen because it provides the
opportunity to study TS and Ki67 expression levels in
relation to the morphological features of the areas
examined.2. Materials and methods
2.1. Cases
The clinical records of 50 patients who underwent sur-
gery for previously untreated colorectal adenocarcinoma,
during the time period of January 1999 to December
2003, were reviewed and are summarised in Table 1. No
patient had received any prior chemotherapy. Before
starting the study, the patients consent was obtained.
Our study was performed using formalin-ﬁxed, paraf-
ﬁn-embedded primary tumour samples, retrieved from
archival material and belonging to our computerised
registry of approximately 350 cases of CRC. We in-
cluded in our observations, all cases previously diag-
nosed as ‘‘signet ring cell colorectal carcinomas’’ in the
abovementioned time period.The histopathological features of the patients tu-
mours were evaluated by two diﬀerent pathologists
and classiﬁed as follows:
Group (A) 20 cases were of the intestinal type, of which
6 were well diﬀerentiated, 7 were moderately
diﬀerentiated and 7 undiﬀerentiated;
Group (B) 15 cases were the signet ring cell type;
Group (C) 15 cases were mixed-type, showing at least
two diﬀerent histological components: 8
cases showed mucinous and intestinal areas,
3 cases showed mucinous, intestinal, and
signet ring cell areas and 4 cases showed
mucinous and signet ring cell areas.
Each histological component should be present in not
less than 10 microscopic high-power ﬁelds (HPFs). Each
HPF identiﬁes the area of the microscopic ﬁeld evalu-
ated by a 40X lens. (1 HPF = 0.159 mm2).
We did not ﬁnd any pure mucinous tumours because
at least 10 HPFs showing intestinal and/or signet ring
cell components were found in every case with a pre-
dominantly mucinous pattern.
2.2. Immunohistochemistry assay
For each case, 10 5-lm sections were used from
formalin-derived ﬁxed tissue blocks, that were de-
waxed and rehydrated. Antigen retrieval was carried
out using Dako antigen retrieval ﬂuid and by micro-
waving at full power for a total of 15 min, divided
into 3 periods of 5 min each. Distilled water was
added between each 5 min of microwaving. Sections
were then treated with 3% hydrogen peroxidase for
5 min, followed by TS 106 (purchased from Neo-
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was used at a dilution of 1:10 overnight at 4 C. Vis-
ualisation was obtained by incubation with anti-mouse
rabbit and goat antibody (Dako) for 15 min, followed
by a streptavidin–biotin peroxidase complex (Dako)
for 15 min. Finally, Dako chromogen was added for
5 min. Mayers haematoxylin was used to counterstain
the sections. The same TS protocol was used for the
antibody Ki67 (purchased from Dako) and used at a
dilution 1:50 for 1 h.
As a positive control for both TS and Ki67 stain-
ing, we used lymphoid germinal centre cells and nor-
mal mucous glands that were present adjacent to
tumour. TS staining was evaluated as being positive
when the intensity of staining (cytoplasmatic and/or
nuclear) was P the control intensity of staining.
Negative controls, stains that lacked primary anti-
body incubations, were included for every
experiment.
TS-positivity for every patient enrolled in groups A
and B was evaluated in 10 microscopic HPFs in which
the neoplastic epithelial area should be more than 70%
of the whole ﬁeld. For each ‘‘mixed-type’’ carcinoma
(group C), the evaluation of TS staining was performed
separately on 10 HPFs for every histological
component.
TS-positivity was evaluated semi-quantitatively as
follows:
1. Strongly positive (+++): if more than 50% of the neo-
plastic areas were positive.
2. Mildly positive (+/++): if 10–50% of neoplastic areas
were positive.
3. Negative (/+): if less than 10% of the neoplastic
areas were positive.
In the negative samples (samples with less than 10%
of the neoplastic areas staining positive for TS), single
positive cells were counted in 40 HPFs and the mean va-
lue in each HPF was reported.
Positivity for Mib1 was evaluated according to the
percentage of cells showing detectable staining. A
semi-quantitative score was adopted:
High proliferation index (+++): if more than 50% of
nuclei were positive.
Medium proliferation index (+/++): if 10–50% of nu-
clei were positive.
Low proliferation index (/+): if less than 10% of nu-
clei were positive.
2.3. Statistical analysis
Diﬀerences in the distribution of the study variables
and associations between variables were assessed by
means of the v2 test, with Yates correction when
appropriate.3. Results
3.1. Evaluation of TS and Mib1 expression
All of the intestinal type carcinomas (group A), inde-
pendent of the grade of diﬀerentiation, showed a wide-
spread positivity in over 50% of the neoplastic areas
evaluated in 10 HPFs and were classiﬁed as positive
for TS staining (+++). Mib1 was also present in more
than 50% of nuclei, indicating a high proliferation index
(+++) (see Fig. 1).
The signet ring cell carcinomas (group B) showed
very low TS-positivity, in less than 10% of neoplastic
areas, and very low Mib1-positivity, below 2% of nuclei
staining (range of positivity 0–10%). They were classiﬁed
as negative (/+) for TS and Mib1 staining (Table 2).
When a count of the absolute number of positive cells
was performed in the rare positive areas, the TS staining
was very scant and it was mainly nuclear (mean = 4
cells · HPF, range = 0–9).
Poor TS and Mib1 expression was more often present
in a few undiﬀerentiated cells with large nuclei and little
cytoplasm, which were mainly localised in the surface
areas of the tumours, whilst cells with a clear ‘‘signet
ring’’ morphology were very rarely positive.
Group C showed a diﬀerent TS and Mib1 expression
pattern in diﬀerent histological components: the intesti-
nal type areas were always positive for TS and Mib1
(+++), the ‘‘signet ring cell’’ areas were almost always
negative (/+); the mucinous areas were heterogeneous
for TS expression (ranging from /+ to +++) and
showed a medium proliferation index (Mib1 = +/++).
Statistical analysis showed a signiﬁcant diﬀerence be-
tween intestinal and signet ring cell cases (groups A and
B) (v2 = 44.4, P < 0.0001).
By combining the immunohistochemical results in the
histological areas of the pure carcinomas (groups A and
B) with the results of analogous histological areas of
mixed carcinomas (group C), a statistically signiﬁcant
diﬀerence was obtained between intestinal and signet
ring cell areas (v2 = 44.4, P < 0.0001) for both TS and
Mib1 expression.
Moreover, a statistically signiﬁcant association be-
tween TS and Mib1 expression in intestinal and signet
ring cell areas was found (v2 = 44.4, P < 0.0001)
(Table 3).4. Discussion
Until now, the modulation of 5FU with folinic
acid has been the main therapy for CRC, but only
20–40% of advanced tumours will respond to this
treatment [1]. Moreover, despite adjuvant 5FU the-
rapy, approximately 30% of patients with Interna-
tional Union against Cancer (UICC) stage II and
Fig. 1. (a, b) Intestinal type CRC: strong TS staining (a) and Mib1 staining (b) Original magniﬁcation: 200· (c, d) Signet ring cell type CRC;
negativity for TS (c) and Mib1 (d) in the centre and the left-hand side of the frames. Original magniﬁcation: 400·. Observe positive non-neoplastic
glands on the right-hand side of the frames (positive controls).
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tions of 5FU combined with oxaliplatin and/or iri-
notecan have been introduced, but 5FU is, to date,
the most common chemotherapeutic agent used in
treatment protocols.
The diﬀerent response rates to 5FU have resulted in
the need for prognostic markers to deﬁne those patients
most likely to beneﬁt from chemotherapy. Particular
care has been focused on the expression of TS, a crucial
target for 5FU in the pathway of pyrimidine synthesis,
which is necessary for DNA synthesis. TS expression
has been associated with clinical outcome in local and
disseminated colorectal cancers.
Previous studies have shown that patients with ad-
vanced and/or metastatic disease and high TS contents
(probably associated with TS gene ampliﬁcation) doTable 2
TS- and Mib1-positivity in groups A and B
Histotype TS Mib1
Group A: 20 cases (intestinal) +++ +++
Group B: 15 cases (signet ring cell) /+ /+
(+++) = positivity > 50% of neoplastic areas for TS; positivity > 50%
of nuclei for Mib1(Ki67)
(/+) = positivity < 10% of neoplastic areas for TS; positivity = 10%
of nuclei for Mib1 (Ki67)
(Statistically signiﬁcant diﬀerence between intestinal type and signet
ring cell carcinomas: v2 = 44.4, P < 0.0001).not respond to 5FU [13–19]. However, many patients
with low TS expression also fail to respond to treatment
[20].
Other adjuvant treatment studies have stated that pa-
tients with high TS levels may beneﬁt from adjuvant
5FU-based chemotherapy [21–23], whereas patients with
low TS levels seem to have a worse outcome when trea-
ted with such adjuvant chemotherapy [22]. These data
agree with recent adjuvant therapy studies in pancreatic
[24] and breast cancers [25].
Our study showed that all CRCs of intestinal types
(irrespective of the grade of diﬀerentiation or intestinal
location) and approximately half of the mucinous carci-
nomas were positive for TS.
By contrast, all SRCCs (irrespective of the intestinal
location) were negative for TS (weak cytoplasmic or nu-Table 3
Group C: TS and Mib1 expression in the mixed-type carcinomas
TS Mib1
Intestinal type areas +++ +++
Signet ring cell /+ /+
Mucinous /+, +/++, +++ +/++
(+++) = positivity > 50% of neoplastic areas for TS, >50% of nuclei
for Mib1
(+/++) = positivity in 10–50% of neoplastic areas for TS, in 10–50% of
nuclei for Mib1
(/+) = positivity < 10% of neoplastic areas for TS, <10% of nuclei for
Mib1.
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areas or, sometimes, conﬁned to small tumour cells with
dark-staining cytoplasm, but ‘‘typical’’ signet ring cells
were negative).
TS is a cell cycle enzyme and is present in proliferat-
ing cells [11,12]. Previous experimental observations in
cell lines showed that ‘‘the expression and activity of
the TS protein in asynchronously-growing cancer cells
are signiﬁcantly related to the cell doubling time; the
faster the cell proliferation, the greater the expression
and activity of TS’’ [11].
Our data showed the same relationship between cell
proliferation, (showed by Mib1) and TS-positivity. In
particular, high positivity for both antibodies was found
in intestinal areas; variable TS-positivity and intermedi-
ate Mib1-positivity in mucinous areas, and very low
positivity in signet ring cell areas.
The low TS- and Mib1-positivity in signet ring cell
areas, suggesting a low proliferative activity, was unex-
pected due to the well known aggressiveness of SRCCs.
However, our ﬁndings agree with a previous autoradio-
graphic study studying the labelling index in gastric can-
cers; typical signet-ring cells had a zero labelling index,
suggesting that they were non-cycling cells and were
functionally diﬀerentiated [26].
According to these observations, it can be hypothe-
sised that SRCCs, consist mainly of non-replicating cells
that are in a post-mitotic phase.
Thus, mechanisms other than proliferation, (for
example, a decrease in apoptosis) could be responsible
for the poor prognosis of SRCC, and this needs to be
investigated further.
Our data agree with other experimental studies in
nude mice subcutaneously (s.c.) injected with human
colon cancer HT29 cells, showing that 5FU induced
an accumulation of signet ring cells and a depletion
of the enterocyte stem cell phenotype only. Since very
few signet ring cells were Ki67-positive, the authors
hypothesised that ‘‘The majority of these cells were
non-replicating and thus less sensitive to 5FU treat-
ments’’ [27].
Further, recent studies assessed that cell lines with
faster doubling times had higher TS levels and were sig-
niﬁcantly more sensitive to 5FU [28]. On this basis, we
can hypothesise that since non-replicating signet ring
cells have a low TS content, they could be less sensitive
to 5FU because the target of one of the most important
modes of action of 5FU (that is the ability of the drug to
inhibit DNA synthesis by binding and inactivating the
TS enzyme) is lacking in these cells.
Of course, we underline the necessity to develop a
better understanding of the other possible mechanisms
of the 5FU action in signet ring cells; for example, an in-
crease in the apoptotic pathway. Perhaps in non-prolife-
rating SRCC, this mechanism could be more important
than the inhibition of DNA synthesis.Although data in the literature state that the inci-
dence of primitive SRCC is very low, approximately,
3% of all CRCs [7], a SRC component is often associ-
ated with the intestinal and mucinous histotypes in
mixed carcinomas. We think that TS expression levels
in the diﬀerent histotypes can aﬀect the patients re-
sponse to 5FU, with a likely low eﬃcacy in signet ring
cell areas. If our conclusions are correct, we think it
will be important to note any areas of SRCC present
in the carcinomas. However, clinical studies are neces-
sary to clarify the real meaning of the presence of the
signet ring cell histotype in the patients response to
5FU.Conﬂict of Interest Statement
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